Protalex, Inc. (PRTX)
Stock Price:
$0.0050 USD
0.0000 (0.00%)
Updated Jul 10, 2020 4:00 PM EDT - End of day
Key Info
| Market Cap |
236,625 |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-4.65M |
| Shares Out |
47.33M |
| EPS (ttm) |
-0.12 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Jul 10, 2020 |
| Last Price |
$0.0050 |
| Previous Close |
$0.0050 |
| Change ($) |
0.0000 |
| Change (%) |
0.00% |
| Day's Open |
- |
| Day's Range |
0.0050 - 0.0100 |
| Day's Volume |
0 |
| 52-Week Range |
0.0015 - 0.0490 |
More Stats
| Market Cap |
236,625 |
| Enterprise Value |
2.35M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
47.33M |
| Float |
6.15M |
| EPS (basic) |
-0.13 |
| EPS (diluted) |
-0.12 |
| FCF / Share |
-0.06 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
-2.06 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
48.10 |
| Revenue |
n/a |
| Operating Income |
-4.06M |
| Net Income |
-4.65M |
| Free Cash Flow |
-2.94M |
| Net Cash |
-2.12M |
| Net Cash / Share |
-0.04 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-732.51% |
| ROE |
n/a |
| ROIC |
-395.70% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -4.42 | -4.01 | -8.98 | -11.30 | -11.57 | -5.62 | -3.50 | -2.64 | -2.97 | -7.29 |
| Net Income | -5.04 | -4.56 | -9.42 | -11.62 | -11.85 | -6.28 | -4.44 | -3.36 | -3.07 | -7.23 |
| Shares Outstanding | 33.55 | 28.77 | 28.77 | 28.77 | 26.22 | 18.93 | 18.93 | 15.77 | 10.54 | 5.72 |
| Earnings Per Share | -0.15 | -0.16 | -0.33 | -0.40 | -0.45 | -0.33 | -0.23 | -0.22 | -0.29 | -1.25 |
| Operating Cash Flow | -3.38 | -3.94 | -4.28 | -3.99 | -4.62 | -4.73 | -2.35 | -2.81 | -3.32 | -6.01 |
| Capital Expenditures | - | - | - | - | - | - | - | - | 0.02 | 0.20 |
| Free Cash Flow | -3.38 | -3.94 | -4.28 | -3.99 | -4.62 | -4.73 | -2.35 | -2.81 | -3.30 | -5.81 |
| Cash & Equivalents | 0.56 | 0.49 | 0.44 | 0.93 | 1.61 | 2.46 | 0.19 | 1.54 | 2.35 | 2.65 |
| Total Debt | 2.10 | 21.79 | 17.25 | 13.02 | 9.40 | 10.27 | 2.60 | 0.66 | 0.59 | - |
| Net Cash / Debt | -1.55 | -21.30 | -16.81 | -12.09 | -7.78 | -7.81 | -2.41 | 0.88 | 1.76 | 2.65 |
| Assets | 0.63 | 0.60 | 0.50 | 0.99 | 1.67 | 2.51 | 0.24 | 1.59 | 2.40 | 2.87 |
| Liabilities | 2.73 | 22.34 | 17.86 | 13.58 | 9.85 | 11.00 | 3.36 | 1.10 | 1.33 | 1.59 |
| Book Value | -2.10 | -21.74 | -17.36 | -12.59 | -8.18 | -8.50 | -3.12 | 0.49 | 1.07 | 1.28 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Protalex, Inc. |
| Country |
United States |
| Employees |
2 |
Stock Information
| Ticker Symbol |
PRTX |
| Stock Exchange |
US OTC |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers - Other |
| Unique Identifier |
OTCMKTS: PRTX |
| IPO Date |
January 11, 2000 |
Description
Protalex, Inc. focuses on the development of biopharmaceutical drugs for treating autoimmune and inflammatory diseases in the United States. The company targets a range of autoimmune diseases, such as rheumatoid arthritis (RA), immune thrombocytopenia (ITP), psoriasis, myasthenia gravis, chronic idiopathic demyelinating polyneuropathy, and pemphigus. Its lead product candidate is PRTX-100, an immunomodulatory therapy, a highly-purified form of staphylococcal protein A, which is in Phase I/II open-label, dose-escalating study for the treatment of patients with persistent/chronic ITP; and Phase 1b clinical trial for the treatment of RA on methotrexate or leflunomide. The company was founded in 1999 and is based in Florham Park, New Jersey.